A trial investigating partial withdrawal of heart failure therapy in patients with heart failure in remission.
Key facts
- Where
- Genk, Hasselt és Turnhout, BelgiumSee the 3 sites
- Phase
- 4. fázis
Where in Belgium
- Ziekenhuis Oost-LimburgGenk, BelgiumTaking people
- JESSA ZiekenhuisHasselt, BelgiumTaking people
- AZ TurnhoutTurnhout, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ziekenhuis Oost Limburg
- Trial code
- EU 2025-522560-32-01
- Record updated
- 2026. október 9.
- Original description
To investigate the safety and feasibility of heart failure therapy down-titration versus therapy continuation in patients with heart failure in remission.Read full original descriptionShow less
A prospective, randomized, controlled clinical pilot trial investigating the partial down-titration of guideline-directed medical therapy in patients with heart failure in remission
To investigate the safety and feasibility of heart failure therapy down-titration versus therapy continuation in patients with heart failure in remission.
Inclusion: Adults aged ≥ 18 years; Heart failure in remission, defined as heart failure with an improved ejection fraction to an LVEF above 50%, with normalized LV volumes, an NT-proBNP ≤ 250 pg/mL, normal functional capacity, and clinical stability; Patients must receive at least 3 HF therapies (ACEi/ARB/ARNI, BB, and MRA or SGLT2i) for HF, consistent with international HF guidelines. Each therapy must have been titrated to the maximally tolerated dose, stable for at least 6 months prior to screening.
Exclusion: Recent major cardiovascular events such as an acute coronary syndrome, CABG, stroke or TIA in the 90 days before screening; Any sustained ventricular arrythmias within 6 months prior to screening; Albuminuric chronic kidney disease; Uncontrolled hypertension; Atrial fibrillation or atrial flutter with a resting heart rate >110 beats per minute; Patients with a cardiac resynchronization therapy device who have < 98% biventricular pacing during screening; Any untreated valvular heart disease of moderate or greater severity during screening; Presence of any other disease with a life expectancy of < 2 years; Pregnant or lactating women.